Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: (CANCER-COG)
Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: A Prospective Multi-Arm Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jean-Michel GRELLARD
- Phone Number: +33 2 31 45 50 50
- Email: jm.grellard@baclesse.unicancer.fr
Study Contact Backup
- Name: Jeanne RIVERAIN, MD
- Phone Number: +33 2 31 45 50 50
- Email: j.riverain@baclesse.unicancer.fr
Study Locations
-
-
-
Caen, France, 14000
- Recruiting
- Centre François Baclesse
-
Sub-Investigator:
- Dinu STEFAN, MD
-
Principal Investigator:
- Paul LESUEUR, MD
-
Sub-Investigator:
- Julien GEFFRELOT, MD
-
Contact:
- Jeanne RIVERAIN, MD
- Email: j.riverain@baclesse.unicancer.fr
-
Le Havre, France
- Not yet recruiting
- Centre Guillaume Le Conquérant
-
Principal Investigator:
- Paul LESUEUR, MD
-
Contact:
- Paul LESUEUR, MD
- Phone Number: +33 (0) 35 13 66 13
- Email: p.lesueur@cglc.fr
-
Rouen, France
- Not yet recruiting
- Centre Henri Becquerel
-
Sub-Investigator:
- Ovidiu VERESEZAN, MD
-
Contact:
- Sébastien THUREAU, PhD
-
Principal Investigator:
- Sébastien THUREAU, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Patients:
Inclusion Criteria:
- Benign meningioma (grade I), or atypical meningioma (grade II)
- Histologic proven of benign meningioma, atypical meningioma or unequivocal radiological diagnosis of skull base meningioma if biopsy is recused.
- Indication of irradiation validated by a multidisciplinary meeting
- Age >20 years and <65 years
- Expected overall survival >10 years
- Adjuvant or exclusive irradiation is allowed.
- Signed informed consent form
- WHO Performance status equal to 0 or 1
- Patient affiliated to the French social health insurance
- Patient whose neuropsychological abilities allow to follow the requirements of the protocol
Exclusion Criteria:
- Patient with mutation in a known predisposition gene (NF-2, SMARCE-1).
- Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia.
- Other localization than skull base meningioma
- Histology/radiological features rather different than grade I-II meningioma
- Histologic proven grade III meningioma
- Uncontrolled epilepsy
- Contraindication to MRI
- Patient with a history of brain irradiation.
- Patient with a history of cancer in the last five years (excluding skin baso-cellular carcinoma)
- Pregnant/breastfeeding woman
- Any geographical conditions, social and associated psychopathology that may compromise the patient's ability to participate in the study
- Participation in a therapeutic trial evaluating a radiotherapy schedule or a new drug or combination for less than 30 days
- Patient deprived of freedom or under guardianship
- Hypersensibility to Gadolinium
Participants free of brain disease or cancer history:
Inclusion Criteria:
- Subject without any history of neurological disease (cerebral stroke, epilepsy, Intra cranial Neurosurgery procedure, meningioma, pituitary adenoma, Parkinson disease,Dementia…) or absence of personality disorders and progressive psychiatric pathology
- Age >20 years and <65 years
- Signed informed consent form
- WHO Performance status equal to 0 or 1
- Subject affiliated to the French social health insurance
- Subject whose neuropsychological abilities allow to follow the requirements of the protocol
- No major cognitive disorder that may compromise the realization of cognitive evaluations, defined as a MoCA score in accordance with the threshold depending on age and educational level according to the GRECOGVASC normative data
Non-inclusion criteria
- Cerebrovascular pathology, presence of other tumors of the nervous system, congenital malformations of the nervous system, multiple sclerosis, Parkinson's disease, organic psychosis (other than dementia), or schizophrenia
- History of epilepsy with antiepileptic drug
- Subject with a history of brain irradiation
- Subject with a history of cancer in the last five years (Excluding skin baso-cellular carcinoma)
- Pregnant/breastfeeding woman
- Any geographical conditions, social and associated psychopathology that may compromise the subject's ability to participate in the study
- Participation in a therapeutic trial - Subject deprived of freedom or under guardianship
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Cohort "IMRT":
Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
|
Patients receiving normo-fractionated intensity-modulated brain irradiation with or without stereotactic positioning (IMRT, VMAT, Tomotherapy…)
|
|
Other: Cohort "SRT"
Patients receiving hypo-fractionated stereotactic brain irradiation
|
Patients receiving hypo-fractionated stereotactic brain irradiation
|
|
Other: Cohort "PRT"
Patients receiving normo-fractionated proton therapy brain irradiation
|
Patients receiving normo-fractionated proton therapy brain irradiation
|
|
Other: Control cohort
Participants without any meningioma, cancer history or neurological comorbidities
|
Participants without any meningioma, cancer history or neurological comorbidities will undergo cognitive assessment by a trained neuropsychologist, similarly as for patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of cognitive impairment (a total of ≥ 5 impaired z-scores)
Time Frame: 10 years
|
Occurrence of cognitive impairment in comparison with baseline evaluation (before brain irradiation), evaluated with z-scores
|
10 years
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2022-A02097-36
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.